Likmez, an Oral Suspension Formulation of Metronidazole, Now Available

Likmez^™, a ready-to-use oral suspension of metronidazole, has been made available by Kesin Pharma Corporation for patients who have dysphagia, difficulty swallowing, or high taste sensitivities.

Likmez is indicated for the treatment of:

• Symptomatic trichomoniasis caused by Trichomonas vaginalis in adult females and males when the diagnosis is confirmed.
• Asymptomatic trichomoniasis caused by Trichomonas vaginalis in adult females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.
• Acute intestinal amebiasis (amoebic dysentery) and amebic liver abscess in adults and pediatric patients.
• Serious infections caused by susceptible anaerobic bacteria in adults.

The most common adverse reactions for Likmez include nausea, headache, anorexia, vomiting, diarrhea, abdominal cramping, epigastric distress, and constipation. Likmez also carries a Boxed Warning associated with a potential for carcinogenicity. 

Likmez oral suspension is supplied in a 200mL bottle containing 500mg/5mL of metronidazole in a strawberry peppermint flavor. The product does not require refrigeration and has a 24-month shelf life.

“Likmez is for patients and providers who need a liquid option for those faced with adherence obstacles due to taste sensitivities or difficulty swallowing. An increasing number of patients can benefit from a safe and efficacious product that can support medication adherence,” said Narasimhan Mani, President & CEO of Kesin Pharma Corporation.